Total Payments
$679,225
2024 Payments
$40,157
Companies
23
Transactions
178
Medicare Patients
851
Medicare Billing
$257,370
Payment Breakdown by Category
Research$517,970 (76.3%)
Consulting$131,970 (19.4%)
Travel$24,586 (3.6%)
Other$3,200 (0.5%)
Food & Beverage$1,499 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $517,970 | 98 | 76.3% |
| Consulting Fee | $131,970 | 53 | 19.4% |
| Travel and Lodging | $24,586 | 10 | 3.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,200 | 1 | 0.5% |
| Food and Beverage | $1,499 | 16 | 0.2% |
Payments by Type
Research
$517,970
98 transactions
General
$161,255
80 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $255,825 | 45 | $0 (2024) |
| Hoffmann-La Roche Limited | $89,190 | 9 | $0 (2017) |
| Pharmacyclics LLC, An AbbVie Company | $71,745 | 25 | $0 (2021) |
| Acerta Pharma LLC | $60,610 | 26 | $0 (2021) |
| F. Hoffmann-La Roche AG | $54,380 | 5 | $0 (2018) |
| Chugai Pharmaceutical Co., Ltd. | $53,930 | 17 | $0 (2024) |
| Janssen Research & Development, LLC | $42,036 | 7 | $0 (2021) |
| Celgene Corporation | $14,976 | 10 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $7,087 | 6 | $0 (2024) |
| Kite Pharma, Inc. | $6,780 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,157 | 10 | ABBVIE INC. ($30,995) |
| 2023 | $64,528 | 14 | AbbVie Inc. ($30,920) |
| 2022 | $44,795 | 18 | ABBVIE INC. ($37,680) |
| 2021 | $63,770 | 28 | Janssen Research & Development, LLC ($38,395) |
| 2020 | $93,058 | 31 | Pharmacyclics LLC, An AbbVie Company ($55,710) |
| 2019 | $107,400 | 28 | AbbVie, Inc. ($60,395) |
| 2018 | $162,775 | 33 | AbbVie, Inc. ($79,655) |
| 2017 | $102,741 | 16 | Hoffmann-La Roche Limited ($89,190) |
All Payment Transactions
178 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 07/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,025.00 | Research |
| Study: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 06/06/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $8,360.00 | General |
| 06/06/2024 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $398.09 | General |
| 05/21/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $2,160.00 | Research |
| Study: A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 04/17/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $180.41 | General |
| 04/17/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $180.41 | General |
| 04/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $3,915.00 | Research |
| Study: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 04/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $28.00 | General |
| 03/19/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $23,895.00 | Research |
| Study: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 12/08/2023 | Janssen Global Services, LLC | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $85.84 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | In-kind items and services | $12,972.37 | General |
| 10/19/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $11,400.00 | General |
| 10/19/2023 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | In-kind items and services | $665.17 | General |
| 10/19/2023 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $310.75 | General |
| 09/19/2023 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $9,200.00 | Research |
| Study: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma • Category: ONCOLOGY | ||||||
| 08/01/2023 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $2,900.00 | Research |
| Study: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma • Category: ONCOLOGY | ||||||
| 07/18/2023 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $350.00 | Research |
| Study: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma • Category: ONCOLOGY | ||||||
| 05/23/2023 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $8,550.00 | Research |
| Study: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma • Category: ONCOLOGY | ||||||
| 05/01/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $784.00 | General |
| Category: Oncology | ||||||
| 04/18/2023 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma • Category: ONCOLOGY | ||||||
| 03/28/2023 | AbbVie Inc. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $9,420.00 | Research |
| Study: A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma • Category: ONCOLOGY | ||||||
| 01/25/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,070.00 | General |
| 01/11/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $5,320.00 | General |
| 12/06/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $930.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 R R CLL WITH GDC0199 BR | Hoffmann-La Roche Limited | $89,190 | 9 |
| M14-031 | AbbVie, Inc. | $80,645 | 8 |
| PCYC-1142-CA | Pharmacyclics LLC, An AbbVie Company | $59,550 | 12 |
| PH III GDC 199 GA101 VS GCHL IN CLL WITH COMORBIDITIES | F. Hoffmann-La Roche AG | $54,380 | 5 |
| M13-365 | AbbVie, Inc. | $51,620 | 3 |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | Janssen Research & Development, LLC | $38,395 | 4 |
| A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma | AbbVie Inc. | $30,920 | 6 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma | ABBVIE INC. | $28,835 | 3 |
| A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | ABBVIE INC. | $15,105 | 3 |
| M14-031 | AbbVie Inc. | $13,435 | 3 |
| A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (CANOVA) | ABBVIE INC. | $11,500 | 2 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemiax2FSmall Lymphocytic Lymphoma | ABBVIE INC. | $10,675 | 7 |
| Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Pharmacyclics LLC, An AbbVie Company | $4,625 | 5 |
| M12-175 | AbbVie, Inc. | $4,060 | 1 |
| Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) | Pharmacyclics LLC, An AbbVie Company | $3,910 | 5 |
| A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenstrom's Macroglobulinemia (WM) | BeiGene, Ltd. | $3,835 | 2 |
| A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenstrom's Macroglobulinemia (WM) | BeiGene (Suzhou) Co., Ltd. | $3,150 | 1 |
| A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma | ABBVIE INC. | $2,645 | 4 |
| M14-728 | AbbVie, Inc. | $2,225 | 2 |
| A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ABBVIE INC. | $2,160 | 1 |
| PCYC-1143-CA | Pharmacyclics LLC, An AbbVie Company | $2,060 | 2 |
| M13-494 | AbbVie, Inc. | $1,600 | 1 |
| Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma | Pharmacyclics LLC, An AbbVie Company | $1,600 | 1 |
| A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) | Verastem, Inc. | $675.00 | 3 |
| IPI-145-06 | Verastem, Inc. | $450.00 | 1 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ABBVIE INC. | $400.00 | 1 |
| A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia | Acerta Pharma LLC | $170.00 | 1 |
| A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | Acerta Pharma LLC | $85.00 | 1 |
| A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | BeiGene AUS Pty Ltd | $70.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 172 | 573 | $221,965 | $56,838 |
| 2022 | 4 | 219 | 783 | $301,806 | $75,990 |
| 2021 | 6 | 248 | 863 | $310,772 | $81,560 |
| 2020 | 5 | 212 | 587 | $133,583 | $42,983 |
Total Patients
851
Total Services
2,806
Medicare Billing
$257,370
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 48 | 218 | $104,858 | $26,355 | 25.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 153 | $51,255 | $15,415 | 30.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 88 | 202 | $65,852 | $15,068 | 22.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 50 | 285 | $137,085 | $34,449 | 25.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 63 | 233 | $78,055 | $20,401 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 95 | 253 | $82,478 | $20,051 | 24.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 12 | $4,188 | $1,089 | 26.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 96 | 394 | $128,444 | $32,544 | 25.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 63 | 283 | $94,805 | $25,628 | 27.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 46 | 139 | $66,859 | $17,717 | 26.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 18 | $11,700 | $3,161 | 27.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 15 | 16 | $5,584 | $1,507 | 27.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 12 | 13 | $3,380 | $1,002 | 29.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 98 | 302 | $48,420 | $19,380 | 40.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 44 | 199 | $68,257 | $18,055 | 26.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 42 | 57 | $10,160 | $3,929 | 38.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 14 | 14 | $4,970 | $1,225 | 24.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 14 | 15 | $1,776 | $393.48 | 22.2% |
About Dr. David Avigan, M.D
Dr. David Avigan, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952349243.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Avigan, M.D has received a total of $679,225 in payments from pharmaceutical and medical device companies, with $40,157 received in 2024. These payments were reported across 178 transactions from 23 companies. The most common payment nature is "" ($517,970).
As a Medicare-enrolled provider, Avigan has provided services to 851 Medicare beneficiaries, totaling 2,806 services with total Medicare billing of $257,370. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 06/02/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1952349243
Products in Payments
- Venclexta (Drug) $140,150
- VENCLEXTA (Drug) $115,675
- VENCLEXTA (Biological) $89,190
- CALQUENCE (Drug) $60,610
- Imbruvica (Drug) $55,710
- GAZYVA (Biological) $54,380
- IMBRUVICA (Drug) $10,135
- Non-Covered Product (Drug) $7,794
- Ibrutinib (Drug) $5,900
- BRUKINSA (Drug) $3,835
- DARZALEX (Drug) $3,641
- EMPLICITI (Biological) $2,932
- Yescarta (Drug) $2,420
- Leukine (Drug) $2,328
- SARCLISA (Biological) $2,222
- ABECMA (Biological) $2,070
- KEYTRUDA (Biological) $1,600
- Copiktra (Drug) $1,125
- CARVYKTI (Drug) $85.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795
Amir Fathi, M.d, M.D
Hematology & Oncology — Payments: $548,854
Hematology & Oncology $548,854